of ovarian cancer. 6 It also has a high false positive rate in benign gynecological diseases such as ovarian cysts and uterine myomas. 7 Therefore, CA 125 alone is not sufficient for screening and differential diagnosis of ovarian cancer. 8 Given these circumstances, many studies have introduced human epididymis protein 4 (HE4) as a new tumor marker to help diagnose ovarian cancer. [9] [10] [11] In 2010, the US FDA approved the Risk of Ovarian Malignancy Algorithm (ROMA) equation using both CA 125 and HE4 levels and patient menopausal state as a new biomarker for the diagnosis of ovarian cancer. [12] [13] [14] Since then, many studies have reported that the simultaneous testing of HE4 and CA 125 with calculation of ROMA is valuable in the diagnosis of ovarian cancer.
In Korea, the HE4 test has been utilized as a new biomarker for ovarian cancers since 2014. Although many studies have been conducted regarding the diagnostic performance of HE4, CA 125, and ROMA in different countries and races, 12, 15, 16 there is little research on the utility of HE4 and ROMA in Korean women. 17 Therefore, it is necessary to investigate the clinical utility of HE4 and CA 125 and to identify the optimal ROMA cutoff for the diagnosis of ovarian cancer in Koreans.
In this study, we evaluated the diagnostic performance of CA 125, HE4, and ROMA for ovarian cancer in Koreans and set the optimal cutoff for each tumor marker.
| MATERIAL S AND ME THODS

| Study subjects
The HE4 assay was requested for a total of 845 patients who visited 
| Calculation of ROMA value
Using the concentrations of CA 125 and HE4, we calculated ROMA according to the mathematical equations presented below. The cutoff value of the ROMA proposed by the manufacturer was ≥11.4% in premenopausal women and ≥29.9% in postmenopausal women. in stage I, 2 (2.9%) were in stage II, 31 (44.3%) were in stage III, and 18 (25.7%) were in stage IV.
| Statistical analyses
| Tumor marker levels in benign diseases and ovarian cancer
The levels of CA 125 and HE4 in benign gynecological diseases are presented in Table 2 . The level of CA 125 was significantly higher in uterine myoma, adenomyosis, endometrial pathology, and endometriosis of the ovary than in the ovarian cyst/tumor group. Meanwhile, HE4 concentration was statistically higher only in the adenomyosis group compared to the ovarian cyst/tumor group.
The levels of CA 125 and HE4 according to pathologic findings and FIGO stage of ovarian cancer are shown in Table 3 . Within the surface epithelial-stromal tumor group, the level of CA 125 was not statistically different between the endometrioid adenocarcinoma and other subgroups of surface epithelial-stromal tumor. However, the level of HE4 was significantly lower (P = 0.0249) in clear cell adenocarcinoma compared to endometrioid adenocarcinoma as a control group. In the comparison between surface epithelial-stromal tumor and other pathologic types, the level of CA 125 was statistically lower in the germ cell tumors (P = 0.0270); however, the level of HE4 showed no significant difference. In addition, the levels of both tumor markers increased significantly as the FIGO stage progressed.
| Diagnostic performance of each tumor marker for ovarian cancer
To investigate the independent variable significantly related to the diagnosis of ovarian cancer, multivariate logistic regression analysis was performed. For premenopausal patients, patient age and the level of CA 125 were significantly associated with ovarian cancer.
For postmenopausal patients, both CA 125 and HE4 levels were related to diagnosis of ovarian cancer. When evaluating all patients regardless of menopausal state, the levels of CA 125 and HE4 and menopausal state were significant independent variables for the diagnosis of ovarian cancer (Table 4 ).
The diagnostic performance of each tumor marker, ROMA values, and the combinations of these tumor markers are summarized in The sensitivity, specificity, PPV, and NPV from the ROC curve analysis using the default cutoff and the optimal cutoff of each tumor marker are presented in Table 6 . In the premenopausal patient group, when the optimal cutoff (>71.7 U/mL) rather than the default cutoff (>35 U/mL) was applied, the sensitivity was the same, TA B L E 2 CA 125 and HE4 levels according to benign disease from 0.903 to 0.836 with the optimal cutoff (>22.5 U/mL).
Furthermore, the diagnostic accuracy improved to 0.847 from 0.809.
For HE4, despite the decrease in specificity from 0.969 to 0.887, the sensitivity increased from 0.571 to 0.804 when the optimal cutoff (>85.5 pmol/L) was used. Therefore, the diagnostic accuracy improved from 0.770 to 0.846. The sensitivity of ROMA was enhanced from 0.696 to 0.929, while the specificity was reduced from 0.913 to 0.800 when the optimal cutoff was applied. Overall, the diagnostic accuracy increased from 0.805 to 0.865.
In all subjects regardless of menopausal state, the sensitivity of CA 125 improved from 0.714 to 0.814, but the specificity decreased from 0.748 to 0.665 when using the optimal cutoff of >26.6 U/mL.
As a result, the diagnostic accuracy changed from 0.731 to 0.740.
The sensitivity, specificity, and diagnostic accuracy of HE4 were 0.800, 0.938, and 0.869, respectively, and HE4 showed a higher specificity and diagnostic accuracy than CA 125 when the optimal cutoff for HE4 (>79.6 pmol/L) was used.
| D ISCUSS I ON
In this study, we analyzed the diagnostic performance of CA 125, HE4, and the combination of these two markers in the differential diagnosis of benign gynecological diseases and ovarian cancer in Korean patients. In addition, we tried to derive the optimal cutoff suitable for a Korean population. A previous domestic study set the 95th percentile of CA 125, HE4, and ROMA from 1,809 healthy people as the normal cutoff, and then these cutoffs were applied to differentiate 140 patients with ovarian cancer and 123 with benign gynecological diseases. In the same study, the sensitivity and specificity for CA 125 were 0.563 and 0.735 in patients less than 50 years of age and 0.859 and 0.762 in patients 50 years of age or older, respectively. The sensitivity and specificity of HE4 were 0.359 and 0.951, respectively, in patients under the age of 50 and 0.718 and 0.952 in subjects 50 years or older. In addition, the sensitivity and specificity of ROMA were 0.391 and 0.961, respectively, in premenopausal women and 0.845 and 0.800 in postmenopausal patients. 17 Although the specificity in a certain group was high, the sensitivity was lower than 0.4; therefore, this makes it difficult to apply normal cutoff values in actual clinical situations. In contrast, we calculated the optimal cutoff values from gynecological diseases and ovarian cancer patients and applied these optimal cutoff values to diagnose ovarian cancer. As a result, the sensitivity increased to higher than 0.7 in premenopausal patients and higher than 0.8 in postmenopausal women (Table 6) . Meanwhile, we analyzed the levels of CA 125 and HE4 in various benign gynecological diseases. The level of CA 125 was significantly higher in uterine myomas, adenomyosis, endometrial pathologies, and endometriosis of the ovary than in the ovarian cyst/tumor group.
On the other hand, the level of HE4 was statistically high only in the adenomyosis group. In our previous study, Park et al 19, 20 also reported that the levels of CA 125 and HE4 increased in various benign gynecological diseases, especially in adenomyosis. The increase in CA 125 and HE4 concentrations differed according to disease, and an increase in CA 125 was more frequent than an increase in HE4 in benign conditions, as our previous and current studies showed. 19, 20 Therefore, it is considered that the specificity of HE4 is higher than that of CA 125. Furthermore, the degrees of increase in the levels of these tumor markers also varied according to the pathologic type of ovarian cancer. In this study, the level of CA 125 was low in germ These results also demonstrate that the diagnostic performance of tumor markers differed according to the pathologic type of ovarian cancer. 16 As CA 125 and HE4 levels vary in benign gynecological diseases and pathologic types of ovarian cancers, it is desirable to use both tumor markers complementarily for diagnosing ovarian cancer.
In a meta-analysis of 28 studies, Wang et al reported that the sensitivity of HE4 for diagnosing ovarian cancer was 0.763, which was slightly lower than that of CA 125 (0.792); however, the specificity of HE4 was 0.936 and was significantly higher than that of CA 125 (0.821). In addition, they reported the sensitivity and specificity of ROMA as 0.853 and 0.824, respectively. 21 Similar to the meta-analysis, the sensitivity and the specificity of CA 125 in our study were 0.857 and 0.836, respectively, and the sensitivity Bold values imply statistically significant results.
TA B L E 5
Area under the receiver operating characteristics curve for the diagnosis of ovarian cancer and the specificity of HE4 were 0.804 and 0.887 when optimal cutoffs were applied to the postmenopausal patients. Similar to the meta-analysis described above, the sensitivity and the specificity of ROMA were 0.929 and 0.800, respectively, showing better sensitivity than that of CA 125 and HE4 but lower specificity.
Direct comparison of sensitivity and specificity among studies is difficult because of the differences in the types of benign gynecological diseases used as control groups, the stages and pathologic types of ovarian cancer patients, and the cutoff for diagnosing ovarian cancer. However, HE4 would have higher specificity but lower sensitivity than CA 125 based on the results of this and previous studies. Therefore, complementary combinations of the two tumor markers and ROMA would contribute to improving ovarian cancer diagnostic performance.
The aim of this study was to evaluate the diagnostic performance of CA 125, HE4, and ROMA in Korean patients with benign gynecological diseases and ovarian cancer and to search for the ideal combination of CA 125 and HE4 to perform better than conventional ROMA. However, only 70 ovarian cancer patients were included in our study, and little numbers of cases according to the pathologic classifications had to be compared as shown in Table 3 .
Furthermore, only 14 of them were premenopausal. Therefore, deriving an optimal combination statistically superior to ROMA was difficult due to the small number of cases. In this study, the AUC of the combination of CA 125 + HE4 in the premenopausal patient group was 0.847, which was higher than the AUC of ROMA (0.824), but the difference was not statistically significant (P = 0.6440). In the postmenopausal patient group, the AUC of ROMA was 0.935, which was higher than the AUC of CA 125 + HE4 combination (0.927), but the difference was not significant (P = 0.2851). In future studies, observing a large number of ovarian cancer patients could allow derivation of an optimal combination of CA 125 and HE4 that could be helpful for the diagnosis of ovarian cancer in Korean women. Furthermore, more researches should be done to confirm the better diagnostic performance of CA125, HE4, and ROMA when optimal cutoffs are applied.
In conclusion, this study evaluated the diagnostic performance of CA 125, HE4, and ROMA for ovarian cancer in Korean patients, and these markers demonstrated good diagnostic performance.
The diagnostic performance of each marker varied depending on the type of benign gynecological disease and pathologic type of ovarian cancer. Therefore, CA 125, HE4, and ROMA should be used as complementary tests to improve the diagnosis of ovarian cancer. 
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